1 Broadway # 14, Cambridge, MA 02142
Prior to SynDevRx, Brad was president (1993-2006), CEO (2000-2006), chairman of the board (2003-2006) and director (1993-2006) at GlycoGenesys (Russell 2000 and NASDAQ). Under his leadership, the company raised over $80 million in equity financing and co-development funding, completed a partnership deal with Elan Pharmaceuticals, developed one of the first complex carbohydrate cancer drug candidates to be tested clinically and conducted five clinical trials in cancer patients. He grew GlycoGenesys to over 55 employees at its peak, including a subsidiary that developed novel products for the agricultural, consumer and industrial markets.
Brad earned a B.A. degree from the College of Business at Michigan State University.
Eric is the vice president and general counsel of Translational Drug Development, a CRO specializing in oncology clinical trial management and pre-clinical oncology studies. He is also manager of Translational Accelerator, an Arizona-based biotech venture fund. Earlier in his career, he was president and CEO of MCS Biotech Resources, which provides business, legal, administrative and support services to expert medical consultants and startup companies. As in-house counsel with Conseco, he served as legal counsel and business adviser for a significant private equity portfolio and led mergers and acquisitions and associated bank financings.
Eric earned a B.S. degree in education from Miami University (Ohio) and a J.D. from the University of Michigan Law School.
In 1998 Jim co-founded JAM Technologies, a fabless semiconductor company serving the consumer electronics and specialty electronics markets, where he served as vice president of corporate development (1998-2006) and on the board of directors (1998-2003). There, he focused on fundraising, executing licensing transactions and forming strategic co-development partnerships, including with AKM, Intel and Apple. Since 2014, he has served as a consultant to Ariana Pharmaceuticals, which provides healthcare data analytics to the pharmaceutical and biotech markets.
Jim is a founding member of the French-American Biotech Springboard, a professional association working under the auspices of the French-American Chamber of Commerce. He is also an active coach and mentor to numerous startups in the Boston area. Jim has three issued patents, studied engineering and French at the University of Massachusetts Amherst and attended L’Universite Catholique (Angers, France) in 1983.
Before North Channel, he was Co-Portfolio Manager of the Mariner Explorer Fund, a fund of hedge funds focusing on non-traditional investment strategies such as insurance-linked securities, commodities and royalty assets. Prior to joining Mariner Mr. Flynn was a Director and Portfolio Manager for K2 Advisors, a fund of hedge funds firm. Before joining K2, Mr. Flynn worked for Securitas Capital, LLC, a private equity firm focusing on investments in the financial services industry. Mr. Flynn graduated from Yale University in 2000 with a B.A. degree in Economics.
Among Dick’s accomplishments are starting two biopharmaceutical companies, Triton Biosciences Inc. and ILEX Oncology Inc. For each company, he served as CEO for eight years. In addition, he led teams that were responsible for the clinical development of four approved therapies: Betaseron® (for multiple sclerosis), Fludara® and CAMPATH® (both for chronic lymphocytic leukemia) and Clolar® (for acute leukemias). In 2004 Genzyme Corporation acquired ILEX for approximately $1 billion.
Dick has also held senior executive positions at not-for-profit organizations including the Cancer Therapy and Research Center and the Translational Genomics Research Institute. From 2007 to 2012, he was a managing partner at Translational Accelerator, an Arizona-based venture capital investment firm. Currently, he serves on the boards of PAREXEL International, ImaRx Therapeutics, MedTrust and Cell Therapeutics. He holds a master’s degree in chemical engineering from Virginia Tech.